ArticleFrontiers in immunology2025
Induced pemphigus erythematosus after treatment for plaque psoriasis with secukinumab: a case report.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Temporarily induced facial eczema by IL-17 inhibitors: a case report and literature review.Frontiers in allergy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secukinumab is a fully human monoclonal antibody that specifically targets and neutralizes interleukin (IL)-17A, a cytokine typically involved in the mucocutaneous defense against pathogens. Despite its favorable safety profile, serious adverse events such as inflammatory bowel disease, oral pemphigoid-like lesions, and lupus erythematosus have been reported. While widely used for psoriasis treatment, cytokine-based therapies carry a potential risk of triggering autoimmune responses. The precise mechanism by which secukinumab induces pemphigus erythematosus remains unclear but may involve immune dysregulation, autoantibody production, microbiota influences, and genetic susceptibility. We report a case of pemphigus erythematosus occurring in a psoriasis patient during secukinumab therapy, which improved after treatment with methylprednisolone sodium succinate injection, leading to clinical symptom resolution. Clinicians should remain vigilant for potential complications and develop individualized management strategies for patients receiving secukinumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.